1 recruiting. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow VM Oncology, LLC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg) - Head and Neck Carcinoma, Adenoid Cystic Carcinoma | Phase 1 / Phase 2 | Recruiting | VM Oncology, LLC | 242 | 2018-06-08 | 2025-12-11 |
Carcinoma, Adenoid Cystic (1) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Laryngeal Diseases (1) · Lung Neoplasms (1) · Mesothelioma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Salivary Gland Neoplasms (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Tracheal Diseases (1)
Combined Modality Therapy (1) · Tablets (1) · pembrolizumab (1)
Puerto Rico (1) · United States (1)